These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Ethics of randomization]. Arpaillange P; Dion S Biomed Pharmacother; 1984; 38(9-10):426-9. PubMed ID: 6529599 [No Abstract] [Full Text] [Related]
5. Objective response criteria in phase II and phase III studies. Jones WG; Akaza H; Van Oosterom AT; Kotake T Prog Clin Biol Res; 1988; 269():243-60. PubMed ID: 3293063 [No Abstract] [Full Text] [Related]
10. Drug-free research in schizophrenia: an overview of the controversy. Appelbaum PS IRB; 1996; 18(1):1-5. PubMed ID: 11660192 [No Abstract] [Full Text] [Related]
11. Shortcomings of the National Crohn's Disease Study: the exclusion of azathioprine without adequate trial. Korelitz BI; Present DH Gastroenterology; 1981 Jan; 80(1):193-6. PubMed ID: 6108892 [No Abstract] [Full Text] [Related]
12. [Double-blind or open mind?]. Huttunen JK Duodecim; 1986; 102(16):1129-33. PubMed ID: 3757849 [No Abstract] [Full Text] [Related]
15. A new design for randomized trials. Rutstein DD N Engl J Med; 1979 Oct; 301(14):786. PubMed ID: 556240 [No Abstract] [Full Text] [Related]
16. Clinical trial and random error. Urbach P New Sci; 1987 Oct; 116(1583):52-5. PubMed ID: 11655867 [No Abstract] [Full Text] [Related]
17. Randomization designs in comparative clinical trials. Ellenberg SS N Engl J Med; 1984 May; 310(21):1404-8. PubMed ID: 6717522 [No Abstract] [Full Text] [Related]
18. Clinical trials: II. Randomization and sample size. Tilley B; Schork A Henry Ford Hosp Med J; 1985; 33(4):219-24. PubMed ID: 4086332 [No Abstract] [Full Text] [Related]
19. Eligibility exclusions, losses to follow-up, removal of randomized patients, and uncounted events in cancer clinical trials. Gail MH Cancer Treat Rep; 1985 Oct; 69(10):1107-13. PubMed ID: 4042091 [TBL] [Abstract][Full Text] [Related]